1,326 results on '"Singal, Amit G."'
Search Results
2. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
3. Effect of Hospital Cancer Designation on use of Multimodal Therapy and Survival of Metastatic Colorectal Cancer: A State-Wide Analysis
4. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial
5. Author Correction: Hepatocellular carcinoma
6. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study.
7. ASO Visual Abstract: Effect of Hospital Cancer Designation on Use of Multimodal Therapy and Survival of Patients with Metastatic Colorectal Cancer: A State-Wide Analysis
8. Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
9. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
10. Impact of the Early COVID-19 Pandemic on Incidence and Outcomes of Hepatocellular Carcinoma in the United States
11. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer
12. Evolving trends in CT colonography: A 10-year analysis of use and associated factors
13. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk
14. PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer
15. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
16. Advancing Surveillance Strategies for Hepatocellular Carcinoma: A New Era of Efficacy and Precision
17. Systemic Therapies for Hepatocellular Carcinoma in India
18. Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis
19. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
20. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
21. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
22. Hepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis
23. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
24. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC
25. Performance of a Multi-cancer Early Detection Test for Detection of Hepatocellular Carcinoma in Patients With Cirrhosis
26. COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States
27. Hepatocellular Carcinoma Surveillance: Evidence-Based Tailored Approach
28. Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma
29. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States
30. The Authors’ Reply
31. Racial and Ethnic Disparities in Liver Transplantation for Alcohol-associated Liver Diseases in the United States
32. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.
33. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis
34. A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC
35. Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis
36. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
37. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference
38. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era
39. Healthcare Costs for Medicare Patients With Hepatocellular Carcinoma in the United States
40. Breakthroughs in Hepatocellular Carcinoma Therapies
41. No Increase in Colorectal Cancer Screening in 2019 After American Cancer Society Recommends Starting Screening at Age 45
42. Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
43. Precision HCC Surveillance: It Is All in the Number (Needed)
44. Stool-Based Tests Mitigate Impacts of COVID-19 on Colorectal Cancer Screening
45. Clinical Outcomes of Patients With Suspicious (LI-RADS 4) Liver Observations
46. Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay Among Patients With Hepatocellular Carcinoma in the United States
47. Correlation of LI-RADS 3 or 4 Observations with Histopathologic Diagnosis in Patients with Cirrhosis
48. Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C
49. Racial and Ethnic Disparities in Barriers to Care in Patients with Hepatocellular Carcinoma
50. Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.